About migraine therapeutics
Migraine therapeutics caters to the treatment of acute or chronic migraine. It can be either preventive or abortive, that determines the treatment of migraine.
Technavio’s analysts forecast the Global Migraine Therapeutics Market to grow at a CAGR of 5.38% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the migraine therapeutics market. To calculate the market size, the report considers the revenue generated from the sales of therapeutics such as migraine drugs and migraine devices.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Migraine Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Alder BioPharmaceuticals
• Allergan
• Amgen
• Eli Lilly and Company
• Teva Pharmaceutical Industries
Market driver
• Increasing number of patients suffering from migraine
• For a full, detailed list, view our report
Market challenge
• Side effects of migraine drugs
• For a full, detailed list, view our report
Market trend
• Growth in the number of migraine treatment awareness programs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Global migraine drugs market – Market size and forecast 2017-2022
• Global migraine devices market – Market size and forecast 2017-2022
• Market opportunity by product
PART 08: MARKET SEGMENTATION BY TREATMENT
• Preventive treatment
• Abortive treatment
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Growth in the number of migraine treatment awareness programs
• Increase in the availability of late-stage pipeline products
• Rise in the popularity of devices for migraine treatment
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Alder BioPharmaceuticals
• Allergan
• Amgen
• Eli Lilly and Company
• Teva Pharmaceutical Industries
PART 16: APPENDIX
• List of abbreviations
?
?
Exhibit 01: Parent market
Exhibit 02: Global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global migraine therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global migraine therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Global migraine therapeutics market by product – Market share 2017-2022 (%)
Exhibit 19: Comparison by product
Exhibit 20: Global migraine drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Global migraine drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 22: Global migraine devices market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global migraine devices market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Global migraine therapeutics market by geography – Market share 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Migraine therapeutics market in the Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Migraine therapeutics market in the Americas – Year-over-year growth 2018-2022 (%)
Exhibit 30: Migraine therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Migraine therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 32: Migraine therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Migraine therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Vendor landscape
Exhibit 37: Landscape disruption
Exhibit 38: Vendors covered
Exhibit 39: Vendor classification
Exhibit 40: Market positioning of vendors
Exhibit 41: Alder BioPharmaceuticals: Overview
Exhibit 42: Alder BioPharmaceuticals – Business segments
Exhibit 43: Alder BioPharmaceuticals – Organizational developments
Exhibit 44: Alder BioPharmaceuticals – Key offerings
Exhibit 46: Allergan: Overview
Exhibit 47: Allergan – Business segments
Exhibit 48: Allergan – Organizational developments
Exhibit 49: Allergan – Segment focus
Exhibit 50: Allergan – Key offerings
Exhibit 51: Allergan – Key customers
Exhibit 52: Amgen: Overview
Exhibit 53: Amgen – Business segments
Exhibit 54: Amgen – Organizational developments
Exhibit 55: Amgen – Geographic focus
Exhibit 56: Amgen – Key offerings
Exhibit 57: Eli Lilly and Company: Overview
Exhibit 58: Eli Lilly and Company – Business segments
Exhibit 59: Eli Lilly and Company – Organizational developments
Exhibit 60: Eli Lilly and Company – Geographic focus
Exhibit 61: Eli Lilly and Company – Segment focus
Exhibit 62: Eli Lilly and Company – Key offerings
Exhibit 63: Teva Pharmaceutical Industries: Overview
Exhibit 64: Teva Pharmaceutical Industries – Business segments
Exhibit 65: Teva Pharmaceutical Industries – Organizational developments
Exhibit 66: Teva Pharmaceutical Industries – Geographic focus
Exhibit 67: Teva Pharmaceutical Industries – Segment focus
Exhibit 68: Teva Pharmaceutical Industries – Key offerings
